Evidence map›Paper›PMID 35008350›Full record

ArticleCancers2021

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma.

Ambreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Thomas U Marron, Tomi Jun, Anwaar Saeed, Hannah Hildebrand and 29 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 7 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 7 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. The prevalence of oral mucositis after radiotherapy in patients with Head and Neck Cancer and its associated factors: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  9. Circular RNAs in ferroptosis regulation and tumor progression of gynecological and breast cancers: molecular mechanisms and therapeutic potential.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 16 institutions in 7 countries.

Ambreen MuhammedDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.ORCID 0000-0002-6285-7670
Claudia Angela Maria FulgenziDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.ORCID 0000-0002-5654-9225
Sirish DharmapuriDepartment of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY 10029, USA.
Matthias PinterDepartment of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-7260-532X
Lorenz BalcarDepartment of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-6708-3061
Bernhard ScheinerDepartment of Internal Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-4904-5133
Thomas U MarronDepartment of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY 10029, USA.ORCID 0000-0001-5903-8191
Tomi JunDepartment of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY 10029, USA.
Anwaar SaeedDivision of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Westwood, KS 66205, USA.
Hannah HildebrandDivision of Medical Oncology, Department of Medicine, Kansas University Cancer Center, Westwood, KS 66205, USA.
Mahvish MuzaffarDivision of Hematology/Oncology, East Carolina University, 600 Moye Boulevard, Greenville, NC 27834, USA.ORCID 0000-0002-2619-7724
Musharraf NavaidDivision of Hematology/Oncology, East Carolina University, 600 Moye Boulevard, Greenville, NC 27834, USA.
Abdul Rafeh NaqashDivision of Hematology/Oncology, East Carolina University, 600 Moye Boulevard, Greenville, NC 27834, USA.
Anuhya GampaSection of Gastroenterology, Hepatology & Nutrition, The University of Chicago Medicine, 5841 S. Maryland Ave, Chicago, IL 60637, USA.
Umut OzbekDepartment of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Junk-Yi LinDepartment of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ylenia PeroneDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.
Bruno VincenziDepartment of Medical Oncology, University Campus Bio-Medico, 00128 Rome, Italy.
Marianna SillettaDepartment of Medical Oncology, University Campus Bio-Medico, 00128 Rome, Italy.
Anjana PillaiSection of Gastroenterology, Hepatology & Nutrition, The University of Chicago Medicine, 5841 S. Maryland Ave, Chicago, IL 60637, USA.
Yinghong WangDepartment of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Uqba KhanDivision of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, 1305 York Avenue, Room Y1247, New York, NY 10021, USA.
Yi-Hsiang HuangDivision of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang Ming Chiao Tung University School of Medicine, Taipei 11217, Taiwan.ORCID 0000-0001-5241-5425
Dominik BettingerDepartment of Medicine II, Faculty of Medicine, Medical Center University of Freiburg, University of Freiburg, 79106 Freiburg, Germany.
Yehia I AbugabalDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ahmed KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-9491-0587
Tiziana PressianiMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
Nicola PersoneniMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.ORCID 0000-0002-7995-272X
Lorenza RimassaMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.ORCID 0000-0001-9957-3615
Naoshi NishidaDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan.
Luca Di TommasoHumanitas Clinical and Research Center IRCCS, Pathology Unit, 20089 Rozzano, Italy.ORCID 0000-0002-9013-4728
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan.ORCID 0000-0002-4102-3474
Arndt VogelDepartment of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0003-0560-5538
Francesco A MauriDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.
Alessio CortelliniDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.
Rohini SharmaDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.ORCID 0000-0003-2441-549X
Antonio D'AlessioDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.ORCID 0000-0002-9164-3671
Celina AngDepartment of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY 10029, USA.
David J PinatoDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.ORCID 0000-0002-3529-0103
Hammersmith Hospital · GBHumanitas University · ITMount Sinai Hospital · USEast Carolina University · USMedical University of Vienna · ATThe University of Texas MD Anderson Cancer Center · USUniversità Campus Bio-Medico · ITIcahn School of Medicine at Mount Sinai · USKindai University · JPThe University of Kansas Cancer Center · USUniversity of Chicago · USIRCCS Humanitas Research Hospital · ITMedizinische Hochschule Hannover · DENational Yang Ming Chiao Tung University · TWNewYork–Presbyterian Hospital · USUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic inflammation is a hallmark of cancer, and it has a pivotal role in hepatocellular carcinoma (HCC) development and progression. We conducted a retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence of neutrophiles to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR), and prognostic nutritional index (PNI) on overall (OS), progression free survival (PFS), and radiologic responses. In our 362 patients treated with immunotherapy, median OS and PFS were 9 and 3.5 months, respectively. Amongst tested inflammatory biomarkers, patients with NLR ≥ 5 had shorter OS (7.7 vs. 17.6 months,

Indexed as

hepatocellular carcinomainflammatory biomarkersneutrophil-lymphocyte ratioplatelet-lymphocyte ratioprognostic nutritional index

Identifiers

PMID35008350
PMCPMC8750517
OpenAlexW4206584124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.